MLV & Co. Initiates Acorda Therapeutics With Buy

MLV & Co. initiated coverage on

with a Buy rating. The target price for Acorda Therapeutics is set to $58. Acorda Therapeutics shares have gained 8.31% over the past 52 weeks, while the S&P 500 index has surged 13.04% in the same period. Acorda Therapeutics shares rose 4.04% to $38.38 in pre-market trading.